University of Goettingen
Also known as: Armin Goralczyk | Center of Neurological Medicine, Goettingen, Germany | Center of Operative Urology Bremen | Departement of Medical Statistics, University Medical Center Göttingen | Department of Cardiology and Pulmonolog - Universitaetsmedizin Goettingen - 37099 Goettingen, Germany | Department of Pharmacology, Klinikum Bremen Mitte, Bremen, Germany | Department of Psychiatry and Psychotherapy, Georg-August-University, Germany | Dept. of Clinical Pharmacology, Georg-August-University of Goettingen, Robert-Koch-Str. 40, 37075 Goettingen, Germany | Gastroenterology and Endocrinology, University Medicine of Goettingen | Georg-August-University | Herzzentrum Goettingen | Herzzentrum Goettingen, Cardiology and Pneumology | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | Karsten Gavenis | Klinikum Bremen Mitte | Klinikum Bremen-Mitte, gGmbH | Klinikum Bremen-Mitte gGmbH, Medizinische Klinik I, Bremen, Germany | Medical Statistics, University Medicine of Goettingen | PFH Private Hochschule Göttingen Germany | Prof. Jürgen Brockmöller | Universitatsklinikum Gottingen | University Goettingen | University Hospital Goettingen | University Medical Center Göttingen | University Medical Center Goettingen | University Medical Center Goettingen, Department Nephrology and Rheumatology | University Medical Center Goettingen, Goettingen | University Medical Center Göttingen | University Medical Center Gottingen, Germany | University Medical Center Göttingen (UMG) | University medicine Goettingen | University Medicine Goettingen, Germany | University of Goettingen | University of Göttingen
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2000Last known activity
Nov 30, 2024
Timeline
1730s
- Jun 1, 1734
University of Goettingen— Founded
Drugs by trial phase (71 distinct, 51 trials)
Phase 4 (18 own, 0 via acquisition)
Phase 3 (18 own, 0 via acquisition)
Phase 2 (18 own, 0 via acquisition)
Phase 1 (16 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Affective Symptoms
- Aggression
- Alcohol Drinking
- Alcoholism
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anemia, Iron-Deficiency
- Astrocytoma
- Carcinoma, Neuroendocrine
- Communicable Diseases
- Dementia
- Depression
- Depressive Disorder
- Disease
- Embolism
- Glioblastoma
- Glioma
- Heart Failure
- Heart Failure, Systolic
- Hypertrophy
- Hypertrophy, Left Ventricular
- Immunoblastic Lymphadenopathy
- Infarction
- Infections
- Lymphadenopathy
- Lymphoma
- Lymphoma, Extranodal NK-T-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Macular Degeneration
- Major Depressive Disorder
- Mental Disorders
- Motor Neuron Disease
- Mucopolysaccharidoses
- Mucopolysaccharidosis II
- Myocardial Infarction
- Neoplasms, Neuroepithelial
- Nephritis, Hereditary
- Neuritis
- Neuroendocrine Tumors
- Obesity
- Optic Neuritis
- Panic Disorder
- Prostatic Neoplasms
- Psychotic Disorders
- Pulmonary Embolism
- Recurrence
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Schizophrenia
- Shock
- Shock, Cardiogenic
- Shock, Septic
- Sinusitis
- Syndrome
- Urinary Tract Infections
Recent trials (50)
- NCT06137378CollaboratorPhase 2Nov 30, 2024
- NCT06279793CollaboratorPhase 2Feb 15, 2024
- NCT05944016Sponsor investigatorPhase 3Dec 31, 2023
- NCT05944016OfficialPhase 3Dec 31, 2023
- NCT05944016Lead sponsorPhase 3Dec 31, 2023
- NCT05698680CollaboratorPhase 4Jan 18, 2023
- NCT05230901Reponsible party - principal investigatorPhase 3Feb 23, 2022
- NCT05230901Lead sponsorPhase 3Feb 23, 2022
- NCT04914208Reponsible party - principal investigatorN/ASep 28, 2021
- NCT04914208Lead sponsorN/ASep 28, 2021
- NCT04524208Lead sponsorPhase 2Dec 1, 2020
- NCT04524208Sponsor investigatorPhase 2Dec 1, 2020
- NCT04524208Overall official - principal investigatorPhase 2Dec 1, 2020
- NCT04575064Sponsor investigatorPhase 2/Phase 3Jun 29, 2020
- NCT04301271CollaboratorPhase 2Mar 31, 2020
Details
- Founded
- Goettingen, DE Jun 1, 1734
- Last known activity
- Nov 30, 2024